Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

A randomized trial of rosuvastatin in the prevention of venous thromboembolism.

Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM.

N Engl J Med. 2009 Apr 30;360(18):1851-61. doi: 10.1056/NEJMoa0900241. Epub 2009 Mar 29.

2.
3.

Statins for primary prevention of venous thromboembolism.

Li L, Zhang P, Tian JH, Yang K.

Cochrane Database Syst Rev. 2014 Dec 18;(12):CD008203. doi: 10.1002/14651858.CD008203.pub3. Review.

PMID:
25518837
4.

Statins for primary prevention of venous thromboembolism.

Li L, Sun T, Zhang P, Tian J, Yang K.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD008203. doi: 10.1002/14651858.CD008203.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;12:CD008203.

PMID:
22161421
5.

Efficacy and safety of rosuvastatin in the management of dyslipidemia.

Rubba P, Marotta G, Gentile M.

Vasc Health Risk Manag. 2009;5(1):343-52. Epub 2009 Apr 8. Review.

8.

Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance?

Rizzo M, Berneis K, Spinas GA, Rini GB, Kapur NK.

Int J Clin Pract. 2009 Mar;63(3):478-85. doi: 10.1111/j.1742-1241.2008.01979.x. Review.

PMID:
19222633
9.

An update on the benefits and risks of rosuvastatin therapy.

Toth PP.

Postgrad Med. 2014 Mar;126(2):7-17. doi: 10.3810/pgm.2014.03.2736. Review.

PMID:
24685964
10.

The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.

Kones R.

Ther Adv Cardiovasc Dis. 2009 Aug;3(4):309-15. doi: 10.1177/1753944709337056. Epub 2009 May 21. Review.

PMID:
19460829
11.

Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis.

Kunutsor SK, Seidu S, Khunti K.

Lancet Haematol. 2017 Feb;4(2):e83-e93. doi: 10.1016/S2352-3026(16)30184-3. Epub 2017 Jan 13. Review.

PMID:
28089655
12.

Moving toward new statin guidelines in a post-JUPITER world: principles to consider.

Ridker PM.

Curr Atheroscler Rep. 2009 Jul;11(4):249-56. Review.

PMID:
19500487
13.

Rosuvastatin in elderly patients.

Davidson MH.

Drugs Aging. 2007;24(11):933-44. Review.

PMID:
17953460
14.
15.

Potential role of statins in the treatment of heart failure.

Katz SD.

Curr Atheroscler Rep. 2008 Aug;10(4):318-23. Review.

PMID:
18606102
16.

[Efficacy and Safety of Rosuvastatin in Patients of Different Risk Groups of Developing Cardiovascular Diseases].

Drapkina OM, Eliashevich SO.

Kardiologiia. 2015;55(2):72-81. Review. Russian.

PMID:
26164992
17.

Statins and prevention of venous thromboembolism: Myth or reality?

Gaertner S, Cordeanu EM, Nouri S, Mirea C, Stephan D.

Arch Cardiovasc Dis. 2016 Mar;109(3):216-22. doi: 10.1016/j.acvd.2015.11.007. Epub 2016 Jan 14. Review.

18.

Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis.

Douketis J, Tosetto A, Marcucci M, Baglin T, Cosmi B, Cushman M, Kyrle P, Poli D, Tait RC, Iorio A.

BMJ. 2011 Feb 24;342:d813. doi: 10.1136/bmj.d813. Review.

19.

Ancestry as a determinant of mean population C-reactive protein values: implications for cardiovascular risk prediction.

Shah T, Newcombe P, Smeeth L, Addo J, Casas JP, Whittaker J, Miller MA, Tinworth L, Jeffery S, Strazzullo P, Cappuccio FP, Hingorani AD.

Circ Cardiovasc Genet. 2010 Oct;3(5):436-44. doi: 10.1161/CIRCGENETICS.110.957431. Epub 2010 Sep 28. Review.

20.

Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies.

Kunutsor SK, Seidu S, Khunti K.

Eur Heart J. 2017 May 21;38(20):1608-1612. doi: 10.1093/eurheartj/ehx107. Review.

Supplemental Content

Support Center